Friday, October 13, 2017 12:16:49 AM
Unfortunately for you, the SMART, EXPERIENCED AND KNOWLEDGEABLE money MBA's know better/ not to invest in WDDD since the market is suggesting the remaining claims have little value.
That's why the company can't seem to even raise money to take out their notes in default -otherwise known as FINANCIAL DISTRESS, and why they have to go to the CAFC first (try to get valued claims back). Let's not forget the 2.5 mil in accrued expenses they have to pay as well, along with future operating costs, and CAFC legal fees! With only 84k in cash! Ie big dilution coming as per their 10Q!
Only retail is buying this and its clear even some of them are selling now.
Many here suggesting 'manipulation' or trying to 'keep the WDDD price down' LOL!
No one is shorting because its financially prohibitive, this has been explained many times. Thus, its RETAIL LONGS WHO ARE SELLING.
A retail long selling would want the price HIGH, when they are SELLING, they don't want to suppress the price! Common sense there I would think? When you sell you want to sell high, not low right? Even a short would want the stock high as they have more room for profit, so this idea that sellers want the share price down is silly. And the volume composition shows its SELLERS moving the price down lol...daily volume composition has shown little buying for over a month, no buyers are selling shares lol... you need shares to sell right? so how can you be wanting to buy, but also selling shares you dont have and not able to short? See how that logic doesn't really work?
Today's volume composition
117k buys
203k sells
31k unknown
Looks to me that someone is choosing to SELL their long position
VWAP was 0.032 cents so its not a like a few trades painted the tape lol
I suggest many here use the data available
LOL
Recent WDDD News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:30:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 06:34:14 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM